LIVIVO - Search results -

Search results

Result 1 - 10 of total 16

Search options

Article ; Online: Synthesis and structure-activity relationships of ticlopidine derivatives and analogs as inhibitors of ectonucleotidase CD39.

Bi, Chunyang / Schäkel, Laura / Mirza, Salahuddin / Sylvester, Katharina / Pelletier, Julie / Lee, Sang-Yong / Pillaiyar, Thanigaimalai / Sévigny, Jean / Müller, Christa E

Bioorganic chemistry

2023 Volume 135, Page(s) 106460

Abstract: Ticlopidine is an antithrombotic prodrug of the thienotetrahydropyridine family. For platelet inhibition it has to undergo oxidative ring-opening by cytochrome P450 enzymes. The resulting thiol reacts with a cysteine residue of the purinergic ... ...

Abstract	Ticlopidine is an antithrombotic prodrug of the thienotetrahydropyridine family. For platelet inhibition it has to undergo oxidative ring-opening by cytochrome P450 enzymes. The resulting thiol reacts with a cysteine residue of the purinergic P2Y
MeSH term(s)	Adenosine Triphosphate ; Ticlopidine ; Adenosine ; Blood Platelets ; Structure-Activity Relationship ; 5'-Nucleotidase/metabolism
Chemical Substances	Adenosine Triphosphate (8L70Q75FXE) ; Ticlopidine (OM90ZUW7M1) ; Adenosine (K72T3FS567) ; 5'-Nucleotidase (EC 3.1.3.5)
Language	English
Publishing date	2023-03-11
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	120080-x
ISSN	1090-2120 ; 0045-2068
ISSN (online)	1090-2120
ISSN	0045-2068
DOI	10.1016/j.bioorg.2023.106460
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 4207: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Article ; Online: Cathepsin-Targeting SARS-CoV-2 Inhibitors: Design, Synthesis, and Biological Activity.

ACS pharmacology & translational science

2024 Volume 7, Issue 2, Page(s) 493–514

Abstract: Cathepsins (Cats) are proteases that mediate the successful entry of SARS-CoV-2 into host cells. We designed and synthesized a tailored series of 21 peptidomimetics and evaluated their inhibitory activity against human cathepsins L, B, and S. Structural ... ...

Abstract	Cathepsins (Cats) are proteases that mediate the successful entry of SARS-CoV-2 into host cells. We designed and synthesized a tailored series of 21 peptidomimetics and evaluated their inhibitory activity against human cathepsins L, B, and S. Structural diversity was realized by combinations of different C-terminal warhead functions and N-terminal capping groups, while a central Leu-Phe fragment was maintained. Several compounds were identified as promising cathepsin L and S inhibitors with
Language	English
Publishing date	2024-01-19
Publishing country	United States
Document type	Journal Article
ISSN	2575-9108
ISSN (online)	2575-9108
DOI	10.1021/acsptsci.3c00313
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Correction to "Cathepsin-Targeting SARS-CoV-2 Inhibitors: Design, Synthesis, and Biological Activity".

ACS pharmacology & translational science

2024 Volume 7, Issue 4, Page(s) 1195–1196

Abstract: This corrects the article DOI: 10.1021/acsptsci.3c00313.]. ...

Abstract	[This corrects the article DOI: 10.1021/acsptsci.3c00313.].
Language	English
Publishing date	2024-03-06
Publishing country	United States
Document type	Published Erratum
ISSN	2575-9108
ISSN (online)	2575-9108
DOI	10.1021/acsptsci.4c00095
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Heparins are potent inhibitors of ectonucleotide pyrophosphatase/phospho-diesterase-1 (NPP1) - a promising target for the immunotherapy of cancer.

Lopez, Vittoria / Schuh, H J Maximilian / Mirza, Salahuddin / Vaaßen, Victoria J / Schmidt, Michael S / Sylvester, Katharina / Idris, Riham M / Renn, Christian / Schäkel, Laura / Pelletier, Julie / Sévigny, Jean / Naggi, Annamaria / Scheffler, Björn / Lee, Sang-Yong / Bendas, Gerd / Müller, Christa E

Frontiers in immunology

2023 Volume 14, Page(s) 1173634

Abstract: Introduction: Heparins, naturally occurring glycosaminoglycans, are widely used for thrombosis prevention. Upon application as anticoagulants in cancer patients, heparins were found to possess additional antitumor activities. Ectonucleotidases have ... ...

Abstract	Introduction: Heparins, naturally occurring glycosaminoglycans, are widely used for thrombosis prevention. Upon application as anticoagulants in cancer patients, heparins were found to possess additional antitumor activities. Ectonucleotidases have recently been proposed as novel targets for cancer immunotherapy. Methods and results: In the present study, we discovered that heparin and its derivatives act as potent, selective, allosteric inhibitors of the poorly investigated ectonucleotidase NPP1 (nucleotide pyrophosphatase/phosphodiesterase-1, CD203a). Structure-activity relationships indicated that NPP1 inhibition could be separated from the compounds' antithrombotic effect. Moreover, unfractionated heparin (UFH) and different low molecular weight heparins (LMWHs) inhibited extracellular adenosine production by the NPP1-expressing glioma cell line U87 at therapeutically relevant concentrations. As a consequence, heparins inhibited the ability of U87 cell supernatants to induce CD4+ T cell differentiation into immunosuppressive Treg cells. Discussion: NPP1 inhibition likely contributes to the anti-cancer effects of heparins, and their specific optimization may lead to improved therapeutics for the immunotherapy of cancer.
MeSH term(s)	Humans ; Heparin/pharmacology ; Immunotherapy ; Anticoagulants ; Heparin, Low-Molecular-Weight/pharmacology ; Heparin, Low-Molecular-Weight/therapeutic use ; Glioma
Chemical Substances	Heparin (9005-49-6) ; Anticoagulants ; Heparin, Low-Molecular-Weight
Language	English
Publishing date	2023-08-29
Publishing country	Switzerland
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2606827-8
ISSN	1664-3224 ; 1664-3224
ISSN (online)	1664-3224
ISSN	1664-3224
DOI	10.3389/fimmu.2023.1173634
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Protein kinase inhibitor ceritinib blocks ectonucleotidase CD39 - a promising target for cancer immunotherapy.

Schäkel, Laura / Mirza, Salahuddin / Winzer, Riekje / Lopez, Vittoria / Idris, Riham / Al-Hroub, Haneen / Pelletier, Julie / Sévigny, Jean / Tolosa, Eva / Müller, Christa E

Journal for immunotherapy of cancer

2022 Volume 10, Issue 8

Abstract: Background: An important mechanism, by which cancer cells achieve immune escape, is the release of extracellular adenosine into their microenvironment. Adenosine activates adenosine A: Methods: We pursued a repurposing approach by screening a self- ... ...

Abstract	Background: An important mechanism, by which cancer cells achieve immune escape, is the release of extracellular adenosine into their microenvironment. Adenosine activates adenosine A Methods: We pursued a repurposing approach by screening a self-compiled collection of approved, mostly ATP-competitive protein kinase inhibitors, on human CD39. The best hit compound was further characterized and evaluated in various orthogonal assays and enzyme preparations, and on human immune and cancer cells. Results: The tyrosine kinase inhibitor ceritinib, a potent anticancer drug used for the treatment of anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer, was found to strongly inhibit CD39 showing selectivity versus other ectonucleotidases. The drug displays a non-competitive, allosteric mechanism of CD39 inhibition exhibiting potency in the low micromolar range, which is independent of substrate (ATP) concentration. We could show that ceritinib inhibits ATP dephosphorylation in peripheral blood mononuclear cells in a dose-dependent manner, resulting in a significant increase in ATP concentrations and preventing adenosine formation from ATP. Importantly, ceritinib (1-10 µM) substantially inhibited ATP hydrolysis in triple negative breast cancer and melanoma cells with high native expression of CD39. Conclusions: CD39 inhibition might contribute to the effects of the powerful anticancer drug ceritinib. Ceritinib is a novel CD39 inhibitor with high metabolic stability and optimized physicochemical properties; according to our knowledge, it is the first brain-permeant CD39 inhibitor. Our discovery will provide the basis (i) to develop more potent and balanced dual CD39/ALK inhibitors, and (ii) to optimize the ceritinib scaffold towards interaction with CD39 to obtain potent and selective drug-like CD39 inhibitors for future in vivo studies.
MeSH term(s)	Adenosine/metabolism ; Adenosine Triphosphate/metabolism ; Antigens, CD/metabolism ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Apyrase/immunology ; Apyrase/metabolism ; Carcinoma, Non-Small-Cell Lung/metabolism ; Humans ; Immunotherapy ; Leukocytes, Mononuclear/metabolism ; Lung Neoplasms/metabolism ; Protein Kinase Inhibitors/pharmacology ; Pyrimidines ; Receptor Protein-Tyrosine Kinases ; Sulfones ; Tumor Microenvironment
Chemical Substances	Antigens, CD ; Antineoplastic Agents ; Protein Kinase Inhibitors ; Pyrimidines ; Sulfones ; Adenosine Triphosphate (8L70Q75FXE) ; Receptor Protein-Tyrosine Kinases (EC 2.7.10.1) ; Apyrase (EC 3.6.1.5) ; ENTPD1 protein, human (EC 3.6.1.5) ; ceritinib (K418KG2GET) ; Adenosine (K72T3FS567)
Language	English
Publishing date	2022-08-15
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2719863-7
ISSN	2051-1426 ; 2051-1426
ISSN (online)	2051-1426
ISSN	2051-1426
DOI	10.1136/jitc-2022-004660
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Development of Anthraquinone Derivatives as Ectonucleoside Triphosphate Diphosphohydrolase (NTPDase) Inhibitors With Selectivity for NTPDase2 and NTPDase3.

Baqi, Younis / Rashed, Mahmoud / Schäkel, Laura / Malik, Enas M / Pelletier, Julie / Sévigny, Jean / Fiene, Amelie / Müller, Christa E

Frontiers in pharmacology

2020 Volume 11, Page(s) 1282

Abstract: Ectonucleoside triphosphate diphosphohydrolases (NTPDases) catalyze the hydrolysis of nucleoside tri- and di-phosphates to mono-phosphates. The products are subsequently hydrolyzed by ecto-5'-nucleotidase (ecto-5'-NT) to nucleosides. NTPDase inhibitors ... ...

Abstract	Ectonucleoside triphosphate diphosphohydrolases (NTPDases) catalyze the hydrolysis of nucleoside tri- and di-phosphates to mono-phosphates. The products are subsequently hydrolyzed by ecto-5'-nucleotidase (ecto-5'-NT) to nucleosides. NTPDase inhibitors have potential as novel drugs, e.g., for the treatment of inflammation, neurodegenerative diseases, and cancer. In this context, a series of anthraquinone derivatives structurally related to the anthraquinone dye reactive blue-2 (RB-2) was synthesized and evaluated as inhibitors of human NTPDases utilizing a malachite green assay. We identified several potent and selective inhibitors of human NTPDase2 and -3. Among the most potent NTPDase2 inhibitors were 1-amino-4-(9-phenanthrylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate (20, PSB-16131, IC
Language	English
Publishing date	2020-08-27
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2587355-6
ISSN	1663-9812
ISSN	1663-9812
DOI	10.3389/fphar.2020.01282
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Sulfated Polysaccharides from Macroalgae Are Potent Dual Inhibitors of Human ATP-Hydrolyzing Ectonucleotidases NPP1 and CD39

Lopez, Vittoria / Schäkel, Laura / Schuh, H. J. Maximilian / Schmidt, Michael S. / Mirza, Salahuddin / Renn, Christian / Pelletier, Julie / Lee, Sang-Yong / Sévigny, Jean / Alban, Susanne / Bendas, Gerd / Müller, Christa E.

Marine drugs. 2021 Jan. 22, v. 19, no. 2

2021

Abstract: Extracellular ATP mediates proinflammatory and antiproliferative effects via activation of P2 nucleotide receptors. In contrast, its metabolite, the nucleoside adenosine, is strongly immunosuppressive and enhances tumor proliferation and metastasis. The ... ...

Abstract	Extracellular ATP mediates proinflammatory and antiproliferative effects via activation of P2 nucleotide receptors. In contrast, its metabolite, the nucleoside adenosine, is strongly immunosuppressive and enhances tumor proliferation and metastasis. The conversion of ATP to adenosine is catalyzed by ectonucleotidases, which are expressed on immune cells and typically upregulated on tumor cells. In the present study, we identified sulfopolysaccharides from brown and red sea algae to act as potent dual inhibitors of the main ATP-hydrolyzing ectoenzymes, ectonucleotide pyrophosphatase/phosphodiesterase-1 (NPP1) and ecto-nucleoside triphosphate diphosphohydrolase-1 (NTPDase1, CD39), showing nano- to picomolar potency and displaying a non-competitive mechanism of inhibition. We showed that one of the sulfopolysaccharides tested as a representative example reduced adenosine formation at the surface of the human glioblastoma cell line U87 in a concentration-dependent manner. These natural products represent the most potent inhibitors of extracellular ATP hydrolysis known to date and have potential as novel therapeutics for the immunotherapy of cancer.
Keywords	adenosine ; glioblastoma ; humans ; hydrolysis ; immunosuppression ; immunotherapy ; macroalgae ; metabolites ; metastasis ; polysaccharides ; Red Sea
Language	English
Dates of publication	2021-0122
Publishing place	Multidisciplinary Digital Publishing Institute
Document type	Article
ZDB-ID	2175190-0
ISSN	1660-3397
ISSN	1660-3397
DOI	10.3390/md19020051
Database	NAL-Catalogue (AGRICOLA)

Order via subito

Article ; Online: Sulfated Polysaccharides from Macroalgae Are Potent Dual Inhibitors of Human ATP-Hydrolyzing Ectonucleotidases NPP1 and CD39.

Lopez, Vittoria / Schäkel, Laura / Schuh, H J Maximilian / Schmidt, Michael S / Mirza, Salahuddin / Renn, Christian / Pelletier, Julie / Lee, Sang-Yong / Sévigny, Jean / Alban, Susanne / Bendas, Gerd / Müller, Christa E

Marine drugs

2021 Volume 19, Issue 2

Abstract	Extracellular ATP mediates proinflammatory and antiproliferative effects via activation of P2 nucleotide receptors. In contrast, its metabolite, the nucleoside adenosine, is strongly immunosuppressive and enhances tumor proliferation and metastasis. The conversion of ATP to adenosine is catalyzed by ectonucleotidases, which are expressed on immune cells and typically upregulated on tumor cells. In the present study, we identified sulfopolysaccharides from brown and red sea algae to act as potent dual inhibitors of the main ATP-hydrolyzing ectoenzymes, ectonucleotide pyrophosphatase/phosphodiesterase-1 (NPP1) and ecto-nucleoside triphosphate diphosphohydrolase-1 (NTPDase1, CD39), showing nano- to picomolar potency and displaying a non-competitive mechanism of inhibition. We showed that one of the sulfopolysaccharides tested as a representative example reduced adenosine formation at the surface of the human glioblastoma cell line U87 in a concentration-dependent manner. These natural products represent the most potent inhibitors of extracellular ATP hydrolysis known to date and have potential as novel therapeutics for the immunotherapy of cancer.
MeSH term(s)	Adenosine Triphosphate/antagonists & inhibitors ; Adenosine Triphosphate/metabolism ; Apyrase/antagonists & inhibitors ; Apyrase/metabolism ; Cell Line, Tumor ; Dose-Response Relationship, Drug ; Humans ; Hydrolysis/drug effects ; Phosphoric Diester Hydrolases/metabolism ; Polysaccharides/chemistry ; Polysaccharides/isolation & purification ; Polysaccharides/physiology ; Pyrophosphatases/antagonists & inhibitors ; Pyrophosphatases/metabolism ; Seaweed/chemistry ; Seaweed/isolation & purification ; Sulfuric Acid Esters/chemistry ; Sulfuric Acid Esters/isolation & purification ; Sulfuric Acid Esters/pharmacology
Chemical Substances	Polysaccharides ; Sulfuric Acid Esters ; Adenosine Triphosphate (8L70Q75FXE) ; Phosphoric Diester Hydrolases (EC 3.1.4.-) ; ectonucleotide pyrophosphatase phosphodiesterase 1 (EC 3.1.4.1) ; Pyrophosphatases (EC 3.6.1.-) ; Apyrase (EC 3.6.1.5) ; ENTPD1 protein, human (EC 3.6.1.5)
Language	English
Publishing date	2021-01-22
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2175190-0
ISSN	1660-3397 ; 1660-3397
ISSN (online)	1660-3397
ISSN	1660-3397
DOI	10.3390/md19020051
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: 2-Substituted thienotetrahydropyridine derivatives: Allosteric ectonucleotidase inhibitors.

Schäkel, Laura / Mirza, Salahuddin / Pietsch, Markus / Lee, Sang-Yong / Keuler, Tim / Sylvester, Katharina / Pelletier, Julie / Sévigny, Jean / Pillaiyar, Thanigaimalai / Namasivayam, Vigneshwaran / Gütschow, Michael / Müller, Christa E

Archiv der Pharmazie

2021 Volume 354, Issue 12, Page(s) e2100300

Abstract: The antithrombotic prodrugs ticlopidine and clopidogrel are thienotetrahydro-pyridine derivatives that are metabolized in the liver to produce thiols that irreversibly block adenosine diphosphate (ADP)-activated ... ...

Abstract	The antithrombotic prodrugs ticlopidine and clopidogrel are thienotetrahydro-pyridine derivatives that are metabolized in the liver to produce thiols that irreversibly block adenosine diphosphate (ADP)-activated P2Y
MeSH term(s)	5'-Nucleotidase/antagonists & inhibitors ; Allosteric Regulation/drug effects ; Apyrase/antagonists & inhibitors ; Enzyme Inhibitors/chemical synthesis ; Enzyme Inhibitors/chemistry ; Enzyme Inhibitors/pharmacology ; GPI-Linked Proteins/antagonists & inhibitors ; Humans ; Structure-Activity Relationship ; Thienopyridines/chemical synthesis ; Thienopyridines/chemistry ; Thienopyridines/pharmacology ; Ticlopidine/pharmacology
Chemical Substances	Enzyme Inhibitors ; GPI-Linked Proteins ; Thienopyridines ; 5'-Nucleotidase (EC 3.1.3.5) ; NT5E protein, human (EC 3.1.3.5) ; Apyrase (EC 3.6.1.5) ; ENTPD1 protein, human (EC 3.6.1.5) ; Ticlopidine (OM90ZUW7M1)
Language	English
Publishing date	2021-10-26
Publishing country	Germany
Document type	Comparative Study ; Journal Article
ZDB-ID	6381-2
ISSN	1521-4184 ; 0365-6233 ; 1437-1014
ISSN (online)	1521-4184
ISSN	0365-6233 ; 1437-1014
DOI	10.1002/ardp.202100300
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Uf I Zs.4: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Nucleotide Analog ARL67156 as a Lead Structure for the Development of CD39 and Dual CD39/CD73 Ectonucleotidase Inhibitors.

Schäkel, Laura / Schmies, Constanze C / Idris, Riham M / Luo, Xihuan / Lee, Sang-Yong / Lopez, Vittoria / Mirza, Salahuddin / Vu, The Hung / Pelletier, Julie / Sévigny, Jean / Namasivayam, Vigneshwaran / Müller, Christa E

Frontiers in pharmacology

2020 Volume 11, Page(s) 1294

Abstract: Nucleoside triphosphate diphosphohydrolase1 (NTPDase1, CD39) inhibitors have potential as novel drugs for the (immuno)therapy of cancer. They increase the extracellular concentration of immunostimulatory ATP and reduce the formation of AMP, which can be ... ...

Abstract	Nucleoside triphosphate diphosphohydrolase1 (NTPDase1, CD39) inhibitors have potential as novel drugs for the (immuno)therapy of cancer. They increase the extracellular concentration of immunostimulatory ATP and reduce the formation of AMP, which can be further hydrolyzed by ecto-5'-nucleotidase (CD73) to immunosuppressive, cancer-promoting adenosine. In the present study, we synthesized analogs and derivatives of the standard CD39 inhibitor ARL67156, a nucleotide analog which displays a competitive mechanism of inhibition. Structure-activity relationships were analyzed at the human enzyme with respect to substituents in the
Language	English
Publishing date	2020-09-08
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2587355-6
ISSN	1663-9812
ISSN	1663-9812
DOI	10.3389/fphar.2020.01294
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito